Based on a preliminary assessment by the board of directors of the Company (the “Board”) of the Group’s unaudited consolidated management accounts for the year ended December 31, 2024 (the “Reporting Period”) and the information currently available to the Board, the Group is expected to record an unaudited revenue ranging from RMB1.25 billion to RMB1.3 billion for the Reporting Period, representing an increase ranging from RMB60 million to RMB110 million or 5% to 9% as compared to the revenue of RMB1.19 billion for the previous year; and the Group is expected to record an unaudited net loss ranging from RMB250 million to RMB290 million, representing a significant decrease in loss ranging from RMB1.66 billion to RMB1.7 billion or 85% to 87% as compared to the net loss of RMB1.95 billion in the previous year. The Board is of the preliminary view that, the increase in revenue was mainly due to the increased revenue from HBV vaccination of the Company, and the decrease in comprehensive net loss was mainly due to the decrease in the amount of significant asset impairment losses and the increase in revenue during the year.